Rare and Ultra Rare Therapeutics
Helped both small- and mid-size pharma manufacturers understand drivers of U.S. coverage and market access for novel orphan therapeutics, including likely adoption by U.S. and global payers.
Helped both small- and mid-size pharma manufacturers understand drivers of U.S. coverage and market access for novel orphan therapeutics, including likely adoption by U.S. and global payers. Various tasks included adoption of innovative pricing arrangements, likely utilization management use, formulary or medical benefit placement, and impact of review by third-party value assessors, including ICER and NICE.
CEO insights
Related articles
Real analysis from people who’ve been there
CMMI Engagement on CGT Model
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.